Close Menu

BMS

NEW YORK (GenomeWeb) — Danaher's Leica Biosystems said today that it has made a deal with Bristol-Myers Squibb to collaborate in developing companion diagnostics to predict which patients will respond to BMS-developed targeted therapies.

Can drugmakers be held liable for failing to aggressively warn consumers that patients with certain genetic markers will not respond or will have limited response to their drugs beyond just mentioning this information in drug labeling?

NEW YORK (GenomeWeb News) – IncellDx and Bristol-Myers Squibb have signed an agreement to develop a molecular test that may eventually be used as a companion diagnostic to identify best responders to an investigational drug in BMS's pipeline.

After appointing a new CEO this summer, SQI Diagnostics is continuing its focus on services to pharmaceutical partners in providing custom multiplex immunogenicity panels, with its pipeline of in vitro diagnostics assays as a second priority, the company said this week.

The Multiple Myeloma Research Foundation is hoping that an open-access research portal containing detailed longitudinal clinical and genomic data from multiple myeloma patients will spur collaborative research that advances much needed molecularly-targeted treatments.

Originally published Aug. 13.
The combined sales from Roche's treatments for HER2-positive breast cancer took the lead for pharmacogenomically targeted cancer drugs during the second quarter.

While RNAi drug developers continue to pursue major indications such as cancer and hepatitis C, a number of these companies are looking to niche diseases as good opportunities to apply the gene-silencing technology.

Two new personalized treatment options are now available for patients with metastatic or unresectable melanoma whose tumors harbor mutations in the BRAF gene.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

Time magazine looks into how liquid biopsies are changing cancer care.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.